How Rescheduling Hydrocodone Combination Products Will Reduce Abuse

Published Online: Wednesday, January 22, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, explains how rescheduling hydrocodone combination products as Schedule II drugs will help reduce levels of abuse.
 
This is the seventh in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Deaths related to oxycodone overdose dropped 25% in Florida after the state adopted a Prescription Drug Monitoring Program to track controlled substance dispensing.
Often considered a consequence of the mother’s illegal drug use, drug withdrawal in babies may also be linked to legally obtained narcotics.
The FDA has outlined the type of studies opioids need to complete to win approval for abuse-deterrence.
Pharmacists are positioned to educate and monitor older patients who are discharged on these medications.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$